about
Nanoparticles for brain drug deliveryA blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD)Cancer and the blood-brain barrier: 'Trojan horses' for courses?The Role of Cell-Penetrating Peptide and Transferrin on Enhanced Delivery of Drug to BrainBrain tumor-targeted drug delivery strategiesPharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)Transporter protein and drug-conjugated gold nanoparticles capable of bypassing the blood-brain barrierBrain delivery of proteins via their fatty acid and block copolymer modificationsSite-specific opening of the blood-brain barrier.Permeability assessment of the focused ultrasound-induced blood-brain barrier opening using dynamic contrast-enhanced MRI.Combinatorial peptide libraries: mining for cell-binding peptides.Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries.Identification of peptide ligands for targeting to the blood-brain barrierHigh-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.Mouse models of neurological disorders: a view from the blood-brain barrier.Mesenchymal migration as a therapeutic target in glioblastoma.A voxelized model of direct infusion into the corpus callosum and hippocampus of the rat brain: model development and parameter analysis.Novel nanomaterials for clinical neuroscience.Glutamate as a neurotransmitter in the healthy brainAgile delivery of protein therapeutics to CNSMultifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cellsIn vivo SELEX for Identification of Brain-penetrating Aptamers.Challenges for blood-brain barrier (BBB) screening.Post-traumatic stress disorder: emerging concepts of pharmacotherapy.Increased nanoparticle-loaded exogenous macrophage migration into the brain following PDT-induced blood-brain barrier disruption.The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection.From the liver to the brain across the blood-brain barrier.Gold nanoparticles to improve HIV drug delivery.Phage display as a tool to discover blood-brain barrier (BBB)-shuttle peptides: panning against a human BBB cellular model.Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.Norrin/Frizzled4 signaling in retinal vascular development and blood brain barrier plasticity.Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia.Vessel microport technique for applications in cerebrovascular research.Cerebral aspergillosis: tissue penetration is the key.Differential receptor-mediated drug targeting to the diseased brain.Receptor-Mediated Drug Delivery Systems Targeting to GliomaWhat should be considered on design of a colon-specific prodrug?Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous systemIn vivo methods to study uptake of nanoparticles into the brain.Nano to micro delivery systems: targeting angiogenesis in brain tumors.
P2860
Q21285117-25F6FBFD-1598-4334-AAE5-FF15C92C500AQ24612655-B64CA4AE-1E61-495C-95A5-C42E8DFEFF6DQ24649731-0325F357-D78C-4D27-9A8F-AA54351E79F3Q26745586-29FC9227-0294-43F5-B1EA-ADCA4E3717DCQ26829741-F64C820F-D7BC-4D33-BBBA-B2DADEDEE69AQ27300391-A0DA4BD7-3269-4063-9773-116D230726B2Q28834214-4A547E8A-E796-4A61-A38B-8EE285BC093EQ30354932-EE7C9E6A-F808-4B54-A171-DAC5A1C478DAQ30434041-E1E000D7-AB4D-4D93-873D-024BB1FCC8BCQ30439286-52ED2814-2FE0-4C1A-B379-1DCF8A3C40D3Q31144876-21A13AFA-A125-4B09-888D-C1623C59F325Q33495327-E99F9FC8-FF6B-4D80-AA93-DCBABD0CC4C2Q33531847-C922F4D0-7EDF-48A3-A72E-94681ADA8EF4Q33626490-66D14C8D-2EAE-483A-853A-689CF680DF9BQ33938994-B8079E41-9769-4CAA-A402-F432AE21D2EDQ34002994-781CDE0A-5C59-40D2-B9C3-D0BF306614C7Q34004520-888AC337-24D9-4A38-A042-AADFA8E4BB59Q34009532-8DEE0EBC-C35B-405E-ACC5-AD895302089BQ34048502-E9D0ECB3-112B-469D-92A8-C329D304669CQ34079647-852FFA76-CE94-4532-95B3-C3D7FA0CD55EQ34227784-67A7C1C3-C8CD-457B-996B-17B46F99E2B6Q34539526-C658FFBE-0760-4619-B19E-67EF203CCA6EQ34707666-FD758FEE-970A-4DE1-B472-08E266BFCE75Q34981801-2591EECD-BE78-430E-91C2-F2160239BE93Q34987685-8931EB09-16A7-4994-8A85-C27A6A41F640Q35275083-4AF7A666-C37C-4A03-8F34-CFFD8112F6F4Q35778166-56E20026-C721-4CE0-A486-6030458DF68EQ35847982-9AA0EDE9-3742-4C96-8D1B-0BFF0057939CQ36093633-AEAE4E05-FB91-4B66-B485-09651701D346Q36111924-B1ECE8DC-243D-4E3A-A867-F987B0BC333DQ36502977-161F4E34-A491-4BCB-BCB6-8A2B6765C579Q37130006-861FE1B4-F886-46AF-AFE3-616280E6CAFCQ37270325-7793DEF1-E82D-4C2D-B2C0-E891CC989AB9Q37405288-2271FD75-DAA6-4D0F-B7F0-844EAD8CDC1DQ37425213-A20532B0-31C1-4CA1-9B31-D8D47B4C058FQ37636271-A93745BB-4C4E-4E75-BA14-2507C53F9BB0Q37679957-D99216C5-D77F-426D-BBE7-D37A734FDA8DQ37698620-68F4E7A3-39EF-4173-A8F7-99B2EB2C2ACDQ37798178-5A431816-DBC0-4793-B1D8-F7FDCD5ACFB9Q37798870-D3C1FB72-DD85-455A-886B-145BE622A6EB
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Drug targeting to the brain.
@ast
Drug targeting to the brain.
@en
type
label
Drug targeting to the brain.
@ast
Drug targeting to the brain.
@en
prefLabel
Drug targeting to the brain.
@ast
Drug targeting to the brain.
@en
P1476
Drug targeting to the brain.
@en
P2093
Gaillard PJ
de Boer AG
P304
P356
10.1146/ANNUREV.PHARMTOX.47.120505.105237
P577
2007-01-01T00:00:00Z